异丙肾上腺素,心脏肥大 z-bo 2020-11-27 291

　　Objective To search for important biomarkers through the serum metabolome and to explore the pathogenesis of cardiac hypertrophy in rats.

　　Method A rat model of cardiac hypertrophy was established by intraperitoneal injection of 30 mg/(kg·d) of isoproterenol for 14 consecutive days. The cardiac mass index was used to evaluate the rat cardiac hypertrophy model. Ultra-performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry was used to detect endogenous metabolites in rat serum, MPP software was used to analyze metabolite differences, Human Metabolome Database (HMDB) database was used to determine biomarkers, and MetaboAnalyst 4.0 was used to analyze metabolic pathways. .

　　Results Intraperitoneal injection of isoproterenol can induce cardiac hypertrophy in rats. There are significant differences in serum metabolites between the cardiac hypertrophy model group and the normal group, and a total of 10 potential biomarkers have been identified. Compared with the normal group, sphingosine-1-phosphate and dihomo-γ-linolenic acid in the cardiac hypertrophy model group were significantly down-regulated, D-fructose-1,6-diphosphate, deoxyadenosine, and N-acetylmethionine , Phytosphingosine, allantoin, 3-keto-β-D-galactose, octane and glycerol were significantly up-regulated.

　　Conclusion Isoproterenol-induced cardiac hypertrophy involves metabolic pathways such as sphingolipid metabolism, glycerolipid metabolism, galactose metabolism, unsaturated fatty acid biosynthesis and purine metabolism. This study provides a reference for revealing the metabolic changes of circulating blood in cardiac hypertrophy induced by isoproterenol.